What is the recommended management of polycystic ovary syndrome, including lifestyle modifications, pharmacologic therapy (e.g., combined oral contraceptives, metformin, anti‑androgens), and fertility treatment options?

Management of Polycystic Ovary Syndrome

Begin immediately with multicomponent lifestyle intervention as the foundational treatment for all women with PCOS, targeting a modest 5% weight loss through dietary modification, structured exercise (150 minutes weekly at moderate-to-vigorous intensity), and behavioral strategies, then layer pharmacologic therapy based on the patient's primary symptoms: combined oral contraceptives for menstrual irregularity and hirsutism, metformin for metabolic dysfunction and cycle regulation when contraceptives are declined, and anti-androgens (spironolactone) for refractory hirsutism with mandatory contraception. 1

Lifestyle Modification: The Essential First Step

Initiate lifestyle intervention immediately—do not postpone this while considering pharmacologic options. 1

• Exercise prescription: 150 minutes per week minimum, with 90 minutes at moderate-to-vigorous intensity (70-90% maximum heart rate, calculated as 220 minus age). 2
• Weight loss target: Achieve 5% reduction in initial body weight to restore ovulation, improve menstrual regularity, and ameliorate metabolic disturbances. 1
• Exercise benefits persist even without weight loss, conferring reproductive and metabolic improvements independently. 1
• Dietary approach: No single dietary pattern proves superior; focus on sustainable caloric reduction and prevention of weight gain rather than specific macronutrient composition. 1
• Practical implementation: Include resistance training 2 times weekly for weight maintenance or 3 times weekly for adolescents; encourage opportunistic activity (stairs, walking, reducing sedentary time). 2

Pharmacologic Management for Menstrual Irregularity

When Contraceptives Are Acceptable

Combined oral contraceptives are first-line pharmacologic therapy for menstrual cycle regulation, providing simultaneous endometrial protection and contraception. 3, 4

• Mechanism: COCPs suppress ovarian androgen production, increase SHBG (reducing free androgen index), and regulate endometrial proliferation. 5
• Biochemical superiority: COCPs significantly outperform metformin for reducing FAI (mean difference 7.08), increasing SHBG (118.61 nmol/L higher), and lowering testosterone (0.48 nmol/L lower). 5
• Formulation preference: Use low-dose preparations to minimize metabolic side effects. 6
• Alternative progestin therapy: For women with contraindications to estrogen, prescribe progestin-only pills or cyclical progestins for endometrial protection. 3

When Contraceptives Are Declined or Contraindicated

Metformin is the preferred medication for menstrual cycle regulation when oral contraceptives cannot be used. 1

• Metabolic benefits: Metformin improves insulin sensitivity, reduces insulin resistance, lowers triglycerides (0.15 mmol/L reduction vs. COCP), and may delay progression to type 2 diabetes. 1, 5
• Dosing: Titrate up to 2000-2550 mg daily as tolerated (typical target 1500-2000 mg daily in divided doses). 7
• Monitoring requirements: Check renal function before initiation and regularly during treatment; assess hematologic parameters for vitamin B12 deficiency. 7
• Critical warnings: Discontinue immediately before surgical or radiological procedures requiring contrast; counsel against excessive alcohol intake due to lactic acidosis risk. 7
• Ovulation restoration: Metformin may induce ovulation in anovulatory women—counsel regarding unintended pregnancy risk and contraception needs. 7

Pharmacologic Management for Hyperandrogenism

Hirsutism and Acne

Combined oral contraceptives are first-line therapy for hirsutism and acne, superior to anti-androgens as monotherapy. 8, 9

• Efficacy: COCPs reduce hirsutism through androgen suppression and SHBG elevation, with effects visible after 6 months minimum. 1, 9
• Combination with mechanical removal: Cosmetic procedures (shaving, waxing, electrolysis, laser) are necessary adjuncts for clinically meaningful hair reduction—pharmacotherapy alone is insufficient. 1

Refractory Hirsutism Requiring Anti-Androgens

Spironolactone is the primary anti-androgen for hirsutism refractory to COCPs after a minimum 6-month trial, or when COCPs are contraindicated. 1, 9

• Alternative anti-androgens: Finasteride or flutamide can be considered, though comparative evidence is limited. 1
• Dosing frequency matters: Daily anti-androgen use is significantly more effective for hirsutism than every-three-day dosing (mean difference -3.48). 9
• Mandatory contraception: All anti-androgen therapies carry teratogenic risk—ensure reliable contraception with barrier methods or progestin-only contraception before prescribing. 1
• Monitoring requirements: Assess potassium levels and renal function before initiating spironolactone and periodically during treatment. 1
• Topical adjunct: Add eflornithine hydrochloride cream for facial hirsutism improvement. 1
• Timeline expectations: Visible hirsutism improvement requires ≥6 months; track response using modified Ferriman-Gallwey scoring. 1

Combination Therapy for Dual Pathophysiology

Concurrent metformin plus anti-androgen (e.g., spironolactone) targets both hyperinsulinemia and hyperandrogenism, offering superior biochemical improvement compared with either agent alone. 1

• Rationale: Addresses the two major endocrine disturbances in PCOS simultaneously. 5
• Metformin + anti-androgen superiority: This combination reduces testosterone more effectively than metformin alone (mean difference -0.29 nmol/L). 9
• COCP + metformin combination: Adding metformin to COCP improves FAI (0.58 lower) and SHBG (16.61 nmol/L higher) compared with COCP alone, while also improving insulin resistance (0.44 lower) and fasting insulin (17.03 pmol/L lower). 5
• Lipid consideration: Combining anti-androgens with COCP may worsen lipid profiles compared with COCP alone—monitor lipids and consider cardiovascular risk factors. 9

Metabolic Screening and Management

Screen all women with PCOS for metabolic syndrome components, as metabolic syndrome occurs twice as frequently in PCOS compared with the general population, and PCOS confers a four-fold increased risk for type 2 diabetes. 4

• Screening parameters: Fasting glucose, insulin, lipid profile, blood pressure, and waist circumference at diagnosis and regularly thereafter. 1
• Metformin indication: Prescribe metformin for women with BMI >25 kg/m² or other high metabolic risk features (insulin resistance, dysglycemia, elevated triglycerides). 8
• Cardiovascular risk: PCOS increases atherosclerotic cardiovascular disease risk, particularly post-menopause; manage dyslipidemia, hypertension, and obesity aggressively with lipid specialists when indicated. 10

Fertility Treatment

For anovulatory infertility, clomiphene citrate or letrozole are first-line ovulation induction agents. 3, 4

• Second-line options: Exogenous gonadotropins or in vitro fertilization for clomiphene/letrozole failure. 3
• Laparoscopic ovarian diathermy: Consider only in special cases (e.g., clomiphene resistance with access to laparoscopy). 3
• Metformin role: No longer recommended as primary ovulation induction therapy. 3

Follow-Up and Monitoring Strategy

Evaluate treatment response every 3-6 months, adjusting therapy based on symptom improvement and tolerability. 1

• Hirsutism tracking: Use modified Ferriman-Gallwey scoring; expect ≥6 months for visible improvement. 1
• Menstrual regularity: Document cycle frequency to assess treatment efficacy. 1
• Metabolic surveillance: Monitor fasting glucose, insulin, lipid profile, and body weight to gauge metformin efficacy and cardiovascular risk. 1

Critical Pitfalls to Avoid

• Never postpone lifestyle intervention—it is the essential foundation before and during pharmacologic therapy. 1
• Never prescribe anti-androgen monotherapy without ensuring effective contraception due to teratogenic risk. 1
• Set realistic expectations: Hirsutism improvement is gradual (≥6 months minimum) and mechanical hair removal remains necessary. 1
• Screen for contraindications: Evaluate renal function before metformin; assess potassium and renal status before spironolactone. 1
• Recognize obesity's central role: Central obesity exacerbates insulin resistance and hyperandrogenism; weight gain accelerates from adolescence, requiring early vigilance. 2
• Avoid using polycystic ovarian morphology or anti-Müllerian hormone for diagnosis in adolescents due to poor specificity. 6